Skip to main content
Equibles
ABUS logo

ABUS · Arbutus Biopharma Corp · Webcasts, Transcripts & Audio

Track ABUS — free

Use ABUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.27 -0.02 (-0.48%) Q3 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$856.68M
Shares
197.85M
Volume · Oct 28 1.34M Avg daily vol (3M) 4.83M

Arbutus Biopharma Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Arbutus Biopharma Corp (ABUS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY24 · Q3
2024-11-21
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Transcript
Positive tone Imdusiran (RNAi therapeutic) in HBV AB-101 oral PD-L1 inhibitor HBV disease burden and unmet need
Revenue
$1.34M
▼ 71.3% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Arbutus Biopharma Corp (ABUS) Q2 2024 Earnings Call Transcript
Positive tone imdusiran Phase 2a combination data AB-101 PD-L1 checkpoint inhibitor Phase 2b clinical development planning
Revenue
$1.73M
▼ 62.9% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript
Positive tone Imdusiran combination trials (Phase 2a) AB-101 Phase 1 clinical development HBV functional cure strategy
Revenue
$1.53M
▼ 77.1% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Arbutus Biopharma Corp (ABUS) Q4 2023 Earnings Call Transcript
Positive tone HBV Pipeline / Imdusiran Strategic Combinations / Partnerships AB-101 PD-L1 Inhibitor
Revenue
$2.15M*
▼ 65.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-12-06
Arbutus Biopharma Corp (ABUS) Q3 2023 Earnings Call Transcript
Revenue
$4.66M
▼ 21.7% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Arbutus Biopharma Corp (ABUS) Q2 2023 Earnings Call Transcript
Revenue
$4.65M
▼ 67.3% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Arbutus Biopharma Corp (ABUS) Q1 2023 Earnings Call Transcript
Revenue
$6.69M
▼ 46.8% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Arbutus Biopharma Corp (ABUS) Q4 2022 Earnings Call Transcript
Revenue
$6.25M*
▲ 94.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Arbutus Biopharma Corp (ABUS) Q3 2022 Earnings Call Transcript
Revenue
$5.95M
▲ 78.2% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Arbutus Biopharma Corp (ABUS) Q2 2022 Earnings Call Transcript
Revenue
$14.24M
▲ 511.5% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Arbutus Biopharma Corp (ABUS) Q1 2022 Earnings Call Transcript
Revenue
$12.58M
▲ 495.4% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-24
Arbutus Biopharma Corp (ABUS) Q4 2021 Earnings Call Transcript
Revenue
$3.21M*
▲ 34.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Arbutus Biopharma Corp (ABUS) Q3 2021 Earnings Call Transcript
Revenue
$3.34M
▲ 119.3% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Arbutus Biopharma Corp (ABUS) Q2 2021 Earnings Call Transcript
Revenue
$2.33M
▲ 53.8% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Arbutus Biopharma Corp (ABUS) Q1 2021 Earnings Call Transcript
Revenue
$2.11M
▲ 41.7% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-25
Arbutus Biopharma Corp (ABUS) Q4 2020 Earnings Call Transcript
Revenue
$2.39M*
▲ 47.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Arbutus Biopharma Corp (ABUS) Q3 2020 Earnings Call Transcript
Revenue
$1.52M
▼ 50.2% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-07
Arbutus Biopharma Corp (ABUS) Q2 2020 Earnings Call Transcript
Revenue
$1.51M
▲ 131.9% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Arbutus Biopharma Corp (ABUS) Q1 2020 Earnings Call Transcript
Revenue
$1.49M
▲ 119.6% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Arbutus Biopharma Corp (ABUS) Q4 2019 Earnings Call
Revenue
$1.62M
▼ 3.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–20 of 20 webcasts
Key facts CIK 1447028 CUSIP 03879J100 13F (30d) 25 filings 25 filers Visit website Investor relations